Skip to main content

The resource decision | A question to investigate

A better solvent must improve the whole process

Changing a solvent can change far more than the label on a drum. Reaction behaviour, isolation, drying, operator exposure and product quality may all move with it. The valuable question is whether a candidate improves the process people actually need to run, at a cost and risk they can support.

In the conversation.

NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.

AI Ethics Now | University of Warwick IATLPharmaphorumTechRadar ProET PharmaFinancial TimesPharmaceutical TechnologyGeneOnlinePharmaTimesManufacturing ChemistDigital HealthDaily BusinessTheBusinessDesk.comStartups MagazineInsider MediaYorkshire PostYork PressBusinessCloud

Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.

Who needs the answer

A process-development lead may want an alternative to a problematic solvent while a manufacturing partner wants predictable operation on existing equipment. Procurement may favour availability and price; quality needs a justified impurity and residual-solvent strategy. A proposed Resource Economics comparison would bring these incentives together around a single reaction or isolation step. The first deliverable should be a shortlist with reasons for rejection, rather than a promise to replace every solvent across a portfolio.

Follow the consequence downstream

Set the boundary from solvent supply through the chosen transformation, work-up, isolation and drying. Record any extra wash, solvent swap or purification introduced by the alternative. A smaller reaction charge can be cancelled by greater downstream use. Compare the same product specification and practical output, including failed or repeated operations. Where a candidate changes crystal form or filtration behaviour, that consequence belongs inside the decision rather than in a later footnote.

Screening is the beginning

ACS solvent tools and ICH residual-solvent guidance address different parts of the choice (American Chemical Society, n.d.; ICH, 2024). The former can inform comparative screening; the latter concerns residues and patient safety. Neither alone identifies the best process. Our proposed analysis would keep hazard, performance, supply and cost as separate dimensions. A candidate should remain visible as a trade-off when it improves one dimension but weakens another, so a development team can judge whether further work is justified.

Follow the residue.
Through the formulation.

A solvent choice reaches beyond the reaction vessel. Two published ICH examples show how several small contributions become one daily exposure.

Acetonitrile · ICH Q3C(R9)Two published worked examples · not NEUVIOR results

One daily product mass.
Three sources of residue.

5.0 g daily product mass in both examples

Trace the arithmetic · Excipient 1

0.9 g/day × 400 ppm ÷ 1,000 = 0.36 mg/day

Only Excipient 1 changes between the examples: 400 to 2,000 ppm. The daily masses and the other two concentrations stay the same.

What should a development team investigate?

Keep the final formulation in view when comparing a solvent route: the ingredient record, removal step and analytical method all need an owner. This reading does not establish which solvent performs best in a reaction or how much drying a process needs.

Inspect the source values, calculation and scope

Daily component exposure in mg = daily component mass in g × concentration in ppm / 1000. Product ppm = summed exposure in mg × 1000 / daily product mass in g. Only the two published examples are shown.

Source values retained from ICH’s two examples
ExampleDrug substanceExcipient 1Excipient 2Product exposure
First published example0.3 g/day
800 ppm
0.9 g/day
400 ppm
3.8 g/day
800 ppm
3.64 mg/day
Second published example0.3 g/day
800 ppm
0.9 g/day
2,000 ppm
3.8 g/day
800 ppm
5.08 mg/day

These are source-worked examples, not NEUVIOR experimental results, a solvent substitution recommendation or an assessment of a medicine. Other quality attributes, practical solvent removal, analytical precision, manufacturing capability and applicable requirements remain part of a product-specific assessment.

Option 1 uses a 10 g daily product-mass basis. Option 2 uses the known maximum daily product mass and the combined residue contribution; it also requires appropriate control of practical removal, analysis and manufacture (ICH, 2024, §3.3). No medicine-specific release conclusion is made here.

The proposed comparison

An initial study would request the process description, current solvent charges, yield history, analytical methods, drying times and known equipment limits. Qualified partners could then design a proportionate experimental comparison of shortlisted candidates against the current process. Hold the relevant product acceptance criteria constant, record repeatability and account for every added material. The decision output would identify which uncertainties can be resolved cheaply and which need a larger development programme or specialist safety assessment.

Make the commercial threshold visible

Report reagent and solvent costs per accepted output alongside vessel occupancy, separation effort and waste treatment. Environmental indicators should include total material intensity and energy demand rather than a single solvent score. The price of a candidate at research scale may differ from a qualified manufacturing supply. Sensitivity to supplier concentration, minimum order sizes and process transfer cost can determine whether an apparently elegant alternative deserves commercial development.

A credible reason to stop

Reject a candidate if it cannot meet the required quality, creates an unresolved handling risk, demands unavailable equipment or shifts the burden into excessive purification. Do not average a serious failure into an attractive overall score. A bounded paid screen should finish with a documented decision: retain, investigate further or discontinue. The customer gains a clearer development choice; an investor gains evidence about where additional capital would be useful, rather than a broad environmental promise.

NEUVIOR Data Analysis

A source.
A question.
A clearer decision.

Useful intelligence keeps its evidence attached.

Our public analysis connects a defined question with named sources, reporting periods and methods. Each source below shows the work available today and the access still needed.

Published-data analysis, research hypotheses and evidence studies are distinct kinds of work. Their meaning should remain clear as the programme grows.

Department for Energy Security and Net Zero | Annual, with revision notices

Greenhouse-gas conversion factors 2026

Which dated factor and accounting boundary fit a measured resource activity?

Dataset retrieved

Official source

American Chemical Society | Green Chemistry Institute | Method reference; inspect dated guidance

Process Mass Intensity method

Which material inputs dominate a process, including water?

Method reference

Official source

European Medicines Agency | On guideline revision

Chemistry of active substances guideline

What process, recovered-material and impurity controls belong in a resource proposal?

Document retrieved

Official source

Explore NEUVIOR Data Analysis

The brief for the next investment decision

A useful candidate comparison would let a process team see which solvent is worth its next development experiment and why. The brief would identify the limiting attribute for each candidate: impurity removal, isolation, drying, equipment compatibility or supply. The decision owner would agree the minimum acceptable performance before results are reviewed. Procurement would check whether the required grade can actually be supplied at the proposed scale. A promising laboratory candidate would therefore have a clear development question, rather than an implied permission to introduce it into a manufacturing batch.

Sources and scope

ACS | Green Chemistry Research Tools

ICH | Residual Solvents Q3C(R9)

European Commission | Annex 15 Qualification and validation

These references inform the questions and boundaries. The study design above is a proposed NEUVIOR approach, not a published result or an installed service. Scope, specialist partners, access, responsibilities and fees would be agreed before any commissioned work.

American Chemical Society (n.d.) Green Chemistry Research Tools. Available at: https://www.acs.org/green-chemistry-sustainability/research-innovation/research-tools.html (Accessed: 14 October 2026).

ICH (2024) Residual Solvents Q3C(R9). Available at: https://database.ich.org/sites/default/files/ICH_Q3C%28R9%29_Guideline_MinorRevision_2024_2024_Approved.pdf (Accessed: 14 October 2026).

Bring us the decision you need to make

A useful first discussion starts with one process, one accountable owner and the choice that needs evidence. Share the decision deadline, the information already available and what a credible result would allow your team to do next.

Another useful angle.

NEWSPerspectives & features